PUBLISHER: GlobalData | PRODUCT CODE: 1410830
PUBLISHER: GlobalData | PRODUCT CODE: 1410830
Hepatitis B Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on Hepatitis B Tests market for the year 2020 and beyond. Hepatitis B is a common cause of liver disease across the globe, and remains a major issue for most of the governments despite the fact that an effective vaccine has been available since 1982. The World Health Organization (WHO) recommends that all infants receive the hepatitis B vaccination and universal vaccinations have now been implemented in numerous countries worldwide. Screening of pregnant women for HBV is standard of care in most countries and considered to be a cost-effective strategy for reducing the risk of transmission to the baby. Women are typically screened during their first trimester of pregnancy. For pregnant women at high-risk of acquiring HBV, testing is sometimes repeated at the beginning of the third trimester (28 weeks) or at the time of delivery.
HBV tests are performed for a number of purposes:
i) screening of suspected infection patients and diagnosis;
ii) monitoring of HBV-positive patients;
iii) screening or pregnant women; and
iv) screening of donors of human cells, tissues, and cellular and tissue-based products (HCT/P).
The Hepatitis B Virus Tests includes Hepatitis B Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests, Hepatitis B Nucleic Acid Amplification Tests (NAATs) and Multi-parameter HIV, Hepatitis B, and Hepatitis C NAATs.
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed Hepatitis B Tests and evolving competitive landscape:
Global, Regional and Country level market specific insights:
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Abbott Laboratories, Bio-Rad Laboratories Inc, Hologic Inc, Quidelortho Corp, Oswaldo Cruz Foundation, Grifols SA, F. Hoffmann-La Roche Ltd, Siemens AG, Qiagen NV, bioMerieux SA, DiaSorin SpA, and others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -
Not Applicable
Not Applicable
Not Applicable